{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-070291","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.582776+00:00","generated_at":"2026-05-21T16:55:09.967167+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Olema Q1 2025: $392.7M cash, net loss $30.4M; palazestrant combo mPFS 13.8 months","bullets":["Cash, cash equivalents, and marketable securities of $392.7M at March 31, 2025; net loss $30.4M.","Updated mPFS from Phase 1b/2: 13.8 months (all patients) and 13.1 months (prior CDK4/6i) for palazestrant+ribociclib.","Phase 3 OPERA-01 top-line data expected in 2026; OPERA-02 in frontline breast cancer to start in 2025.","GAAP R&D expenses $30.6M in Q1 2025, up from $29.9M; non-GAAP R&D $27.3M excluding stock comp.","OP-3136 Phase 1 trial enrollment ongoing; preclinical data at AACR showed activity in ovarian, NSCLC, prostate."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-070291","json":"https://secwatch.observer/filing/0000950170-25-070291.json","markdown":"https://secwatch.observer/filing/0000950170-25-070291.md","text":"https://secwatch.observer/filing/0000950170-25-070291.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000095017025070291/0000950170-25-070291-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000095017025070291/olma-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T16:55:09.967167+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}